Various methodologies, including quantitative PCR and immunohistochemistry, have been employed to measure CBX3 expression levels, revealing a compelling correlation between elevated CBX3 levels and poor prognosis in lung cancer patients. This evidence concerns the gene CBX3 and lung cancer.